NCT01492218已完成不适用
A Prospective, Open-labelled, Non-controlled Observational Study to Assess Patient Satisfaction, Physician Acceptability and Safety of Mixtard® 30 NovoLet® for the Treatment of Diabetes Mellitus
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1,330
- 试验地点
- 1
- 主要终点
- Change in Diabetes Treatment Satisfaction Questionnaire (DTSQ) score
研究概览
简要总结
This study is conducted in Asia. The aim of this study is to assess patient satisfaction after switching to biphasic human insulin 30 treatment using the NovoLet® insulin device as treatment for diabetes mellitus under normal clinical practice setting.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diabetes mellitus (type 1 or type 2)
- •Patient not presently using Mixtard® 30 NovoLet®
排除标准
- 未提供
研究组 & 干预措施
NovoLet®
干预措施: biphasic human insulin 30 (Drug)
结局指标
主要结局
Change in Diabetes Treatment Satisfaction Questionnaire (DTSQ) score
次要结局
- Adverse events
- Technical complaints of NovoLet® device
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Long Term Observation of Patient Satisfaction Post INTRACOR Treatment Based on Patient Perception and Diagnostic DataPresbyopiaNCT01164358Technolas Perfect Vision GmbH105
已完成
不适用
Vivity Insight: A Study of Patient Satisfaction and Visual PerformanceCataractNCT04495049Research Insight LLC60
已完成
4 期
Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy ChangeRelapsing Remitting Multiple SclerosisNCT01317004Novartis Pharmaceuticals61
招募中
不适用
Observational study to evalute patient satisfaction with different oral cannabis productsPatients (cannabis-naïve / cannabis-experienced) with a diagnosed disease for which medical cannabis is indicated in the sense of the Cannabis as Medicine (CAM) Act.DRKS00032743Avextra Pharma GmbH500
终止
4 期
A Comparative Study of Patient Satisfaction Between Continued Administration of Previous Antipsychotics Versus Switched Administration to Paliperidone ER in Non-satisfied Patients With Previous Antipsychotic DrugSchizophreniaNCT01592201Janssen Korea, Ltd., Korea13